The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma
Abstract
OBJECTIVE: To review the current management, outline recent advances and address controversies in the management of hepatocellular carcinoma (HCC). SUMMARY OF BACKGROUND DATA: The treatment of HCC is multidisciplinary involving hepatologists, surgeons, medical oncologists, radiation oncologists, radiologists, interventional radiologists, and other disciplines. Each of these disciplines brings its unique perspective and differing opinions that add to controversies in the management of HCC. METHODS: A focused literature review was performed to identify recent studies on the management of HCC and thereby summarize relevant information on the various therapeutic modalities and controversies involved in the treatment of HCC. RESULTS: The main treatment algorithms continue to rely on hepatic resection or transplantation with controversies involving patients harboring early stage disease and borderline hepatic function. The other treatment strategies include locoregional therapies, radiation, and systemic therapy used alone or in combination with other treatment modalities. Recent advances in locoregional therapies, radiation, and systemic therapies have provided better therapeutic options with curative intent potential for some locoregional therapies. Further refinements in combination therapies such as algorithms consisting of locoregional therapies and systemic or radiation therapies are likely to add additional options and improve survival. CONCLUSIONS: The management of HCC has witnessed significant strides with advances in existing options and introduction of several new treatment modalities of various combinations. Further refinements in these treatment options combined with enrollment in clinical trials are essential to improve the management and outcomes of patients with HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Rahbari, N. N., Garden, O. J., Padbury, R., Brooke-Smith, M., Crawford, M., Adam, R., Koch, M., Makuuchi, M., Dematteo, R. P., Christophi, C., et al. (2011) · Surgery · doi:10.1016/j.surg.2010.10.001 · Cited by 2,319
The model for end-stage liver disease (MELD)
Kamath, P. S., & Kim, R. W. (2007) · Hepatology · doi:10.1002/hep.21563 · Cited by 1,674
Cited by
Circular RNA: a novel biomarker and therapeutic target for human cancers
Lei, B., Tian, Z., Fan, W., & Ni, B. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.28047 · Cited by 313
Artificial Intelligence: Present and Future Potential for Solid Organ Transplantation
Peloso, A., Moeckli, B., Delaune, V., Oldani, G., Andres, A., & Compagnon, P. (2022) · Transplant International · doi:10.3389/ti.2022.10640 · Cited by 67
A gene expression signature to select hepatocellular carcinoma patients for liver transplantation
Pinto-Marques, H., Cardoso, J., Silva, S., Neto, J. L., Gonçalves-Reis, M., Proença, D., Mesquita, M., Manso, A., Carapeta, S., Sobral, M., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005637 · Cited by 20
Metadata
- Authors
- Dhir, M., Melin, A. A., Douaiher, J., Lin, C., Zhen, W. (., Hussain, S. M., Geschwind, J.-F. H., Doyle, M. B. M., Abou-Alfa, G. K., & Are, C.
- Venue
- Annals of Surgery
- Published
- 2016-06
- Volume
- 263
- Issue
- 6
- Pages
- 1112-1125
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2323299577
- Cited by
- 285
- References
- 52
- FWCI
- 22.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1097/sla.0000000000001556
- The paper
- Dhir, M., Melin, A. A., Douaiher, J., Lin, C., Zhen, W. (., Hussain, S. M., Geschwind, J.-F. H., Doyle, M. B. M., Abou-Alfa, G. K., & Are, C. (2016). A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Annals of Surgery. https://doi.org/10.1097/sla.0000000000001556
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.